Zebrafish Models of Cancer Therapy-Induced Cardiovascular Toxicity
Abstract
:1. Introduction
2. Zebrafish as a Model for Cardiovascular Disease
3. Zebrafish as a Model to Study Cancer Biology
4. Zebrafish as a Model for Cancer Therapy-Associated Cardiovascular Toxicity
4.1. Limitations of Cell Culture and Mammalian Models of Cancer Therapy-Associated Cardiotoxicity
4.2. Benefits of Zebrafish as a Model for Cancer Therapy-Associated Cardiovascular Toxicity
4.3. Considerations for Using Zebrafish in the Study of Cancer Therapies
5. Conclusions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- De Boer, R.A.; Meijers, W.C.; van der Meer, P.; van Veldhuisen, D.J. Cancer and heart disease: Associations and relations. Eur. J. Heart Fail. 2019, 21, 1515–1525. [Google Scholar] [CrossRef] [Green Version]
- Vincent, L.; Leedy, D.; Masri, S.C.; Cheng, R.K. Cardiovascular Disease and Cancer: Is There Increasing Overlap? Curr. Oncol. Rep. 2019, 21, 47. [Google Scholar] [CrossRef]
- Curigliano, G.; Cardinale, D.; Dent, S.; Criscitiello, C.; Aseyev, O.; Lenihan, D.; Cipolla, C.M. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J. Clin. 2016, 66, 309–325. [Google Scholar] [CrossRef] [Green Version]
- Cardinale, D.; Colombo, A.; Bacchiani, G.; Tedeschi, I.; Meroni, C.A.; Veglia, F.; Civelli, M.; Lamantia, G.; Colombo, N.; Curigliano, G.; et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 2015, 131, 1981–1988. [Google Scholar] [CrossRef] [Green Version]
- Armstrong, G.T.; Kawashima, T.; Leisenring, W.; Stratton, K.; Stovall, M.; Hudson, M.M.; Sklar, C.A.; Robison, L.L.; Oeffinger, K.C. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J. Clin. Oncol. 2014, 32, 1218–1227. [Google Scholar] [CrossRef]
- Bellinger, A.M.; Arteaga, C.L.; Force, T.; Humphreys, B.D.; Demetri, G.D.; Druker, B.J.; Moslehi, J.J. Cardio-Oncology: How New Targeted Cancer Therapies and Precision Medicine Can Inform Cardiovascular Discovery. Circulation 2015, 132, 2248–2258. [Google Scholar] [CrossRef] [Green Version]
- Liu, Y.; Asnani, A.; Zou, L.; Bentley, V.L.; Yu, M.; Wang, Y.; Dellaire, G.; Sarkar, K.S.; Dai, M.; Chen, H.H.; et al. Visnagin protects against doxorubicin-induced cardiomyopathy through modulation of mitochondrial malate dehydrogenase. Sci. Transl. Med. 2014, 6, 266ra170. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Asnani, A.; Zheng, B.; Liu, Y.; Wang, Y.; Chen, H.H.; Vohra, A.; Chi, A.; Cornella-Taracido, I.; Wang, H.; Johns, D.G.; et al. Highly potent visnagin derivatives inhibit Cyp1 and prevent doxorubicin cardiotoxicity. JCI Insight 2018, 3, e96753. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Howe, K.; Clark, M.D.; Torroja, C.F.; Torrance, J.; Berthelot, C.; Muffato, M.; Collins, J.E.; Humphray, S.; McLaren, K.; Matthews, L.; et al. The zebrafish reference genome sequence and its relationship to the human genome. Nature 2013, 496, 498–503. [Google Scholar] [CrossRef] [Green Version]
- Sarmah, S.; Marrs, J.A. Zebrafish as a Vertebrate Model System to Evaluate Effects of Environmental Toxicants on Cardiac Development and Function. Int. J. Mol. Sci. 2016, 17, 2123. [Google Scholar] [CrossRef] [Green Version]
- Stainier, D.Y.; Lee, R.K.; Fishman, M.C. Cardiovascular development in the zebrafish. I. Myocardial fate map and heart tube formation. Development 1993, 119, 31–40. [Google Scholar] [PubMed]
- Chi, N.C.; Shaw, R.M.; Jungblut, B.; Huisken, J.; Ferrer, T.; Arnaout, R.; Scott, I.; Beis, D.; Xiao, T.; Baier, H.; et al. Genetic and physiologic dissection of the vertebrate cardiac conduction system. PLoS Biol. 2008, 6, e109. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Walsh, E.C.; Stainier, D.Y. UDP-glucose dehydrogenase required for cardiac valve formation in zebrafish. Science 2001, 293, 1670–1673. [Google Scholar] [CrossRef] [PubMed]
- Beis, D.; Bartman, T.; Jin, S.W.; Scott, I.C.; D’Amico, L.A.; Ober, E.A.; Verkade, H.; Frantsve, J.; Field, H.A.; Wehman, A.; et al. Genetic and cellular analyses of zebrafish atrioventricular cushion and valve development. Development 2005, 132, 4193–4204. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Scherz, P.J.; Huisken, J.; Sahai-Hernandez, P.; Stainier, D.Y. High-speed imaging of developing heart valves reveals interplay of morphogenesis and function. Development 2008, 135, 1179–1187. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Milan, D.J.; Jones, I.L.; Ellinor, P.T.; MacRae, C.A. In vivo recording of adult zebrafish electrocardiogram and assessment of drug-induced QT prolongation. Am. J. Physiol. Heart Circ. Physiol. 2006, 291, H269–H273. [Google Scholar] [CrossRef] [PubMed]
- Vornanen, M.; Hassinen, M. Zebrafish heart as a model for human cardiac electrophysiology. Channels 2016, 10, 101–110. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cuni, R.; Parrini, I.; Asteggiano, R.; Conte, M.R. Targeted Cancer Therapies and QT Interval Prolongation: Unveiling the Mechanisms Underlying Arrhythmic Complications and the Need for Risk Stratification Strategies. Clin. Drug Investig. 2017, 37, 121–134. [Google Scholar] [CrossRef] [PubMed]
- Babij, P.; Askew, G.R.; Nieuwenhuijsen, B.; Su, C.M.; Bridal, T.R.; Jow, B.; Argentieri, T.M.; Kulik, J.; DeGennaro, L.J.; Spinelli, W.; et al. Inhibition of cardiac delayed rectifier K+ current by overexpression of the long-QT syndrome HERG G628S mutation in transgenic mice. Circ. Res. 1998, 83, 668–678. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Arnaout, R.; Ferrer, T.; Huisken, J.; Spitzer, K.; Stainier, D.Y.R.; Tristani-Firouzi, M.; Chi, N.C. Zebrafish model for human long QT syndrome. Proc. Natl. Acad. Sci. USA. 2007, 104, 11316–11321. [Google Scholar] [CrossRef] [Green Version]
- Milan, D.J.; Kim, A.M.; Winterfield, J.R.; Jones, I.L.; Pfeufer, A.; Sanna, S.; Arking, D.E.; Amsterdam, A.H.; Sabeh, K.M.; Mably, J.D.; et al. Drug-sensitized zebrafish screen identifies multiple genes, including GINS3, as regulators of myocardial repolarization. Circulation 2009, 120, 553–559. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Milan, D.J.; Peterson, T.A.; Ruskin, J.N.; Peterson, R.T.; MacRae, C.A. Drugs that induce repolarization abnormalities cause bradycardia in zebrafish. Circulation 2003, 107, 1355–1358. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Peal, D.S.; Mills, R.W.; Lynch, S.N.; Mosley, J.M.; Lim, E.; Ellinor, P.T.; January, C.T.; Peterson, R.T.; Milan, D.J. Novel chemical suppressors of long QT syndrome identified by an in vivo functional screen. Circulation 2011, 123, 23–30. [Google Scholar] [CrossRef] [PubMed]
- Wen, D.; Liu, A.; Chen, F.; Yang, J.; Dai, R. Validation of visualized transgenic zebrafish as a high throughput model to assay bradycardia related cardio toxicity risk candidates. J. Appl. Toxicol. 2012, 32, 834–842. [Google Scholar] [CrossRef] [PubMed]
- Bakkers, J. Zebrafish as a model to study cardiac development and human cardiac disease. Cardiovasc. Res 2011, 91, 279–288. [Google Scholar] [CrossRef] [Green Version]
- Xu, X.; Meiler, S.E.; Zhong, T.P.; Mohideen, M.; Crossley, D.A.; Burggren, W.W.; Fishman, M.C. Cardiomyopathy in zebrafish due to mutation in an alternatively spliced exon of titin. Nat. Genet. 2002, 30, 205–209. [Google Scholar] [CrossRef] [PubMed]
- Gerull, B.; Gramlich, M.; Atherton, J.; McNabb, M.; Trombitás, K.; Sasse-Klaassen, S.; Seidman, J.G.; Seidman, C.; Granzier, H.; Labeit, S.; et al. Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. Nat. Genet. 2002, 30, 201–204. [Google Scholar] [CrossRef] [PubMed]
- Shi, X.; Chen, R.; Zhang, Y.; Yun, J.; Brand-Arzamendi, K.; Liu, X.; Wen, X.Y. Zebrafish heart failure models: Opportunities and challenges. Amino Acids 2018, 50, 787–798. [Google Scholar] [CrossRef] [PubMed]
- Becker, J.R.; Robinson, T.Y.; Sachidanandan, C.; Kelly, A.E.; Coy, S.; Peterson, R.T.; MacRae, C.A. In vivo natriuretic peptide reporter assay identifies chemical modifiers of hypertrophic cardiomyopathy signalling. Cardiovasc. Res. 2012, 93, 463–470. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schmidinger, M.; Zielinski, C.C.; Vogl, U.M.; Bojic, A.; Bojic, M.; Schukro, C.; Ruhsam, M.; Hejna, M.; Schmidinger, H. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2008, 26, 5204–5212. [Google Scholar] [CrossRef] [PubMed]
- Ishihara, S.; Onoda, N.; Noda, S.; Asano, Y.; Tauchi, Y.; Morisaki, T.; Kashiwagi, S.; Takashima, T.; Ohira, M. Sorafenib inhibits vascular endothelial cell proliferation stimulated by anaplastic thyroid cancer cells regardless of BRAF mutation status. Int. J. Oncol. 2019, 55, 1069–1076. [Google Scholar] [CrossRef] [Green Version]
- Liang, S.; Yu, H.; Chen, X.; Shen, T.; Cui, Z.; Si, G.; Zhang, J.; Cheng, Y.; Jia, S.; Song, S.; et al. PDGF-BB/KLF4/VEGF Signaling Axis in Pulmonary Artery Endothelial Cell Angiogenesis. Cell. Physiol. Biochem. 2017, 41, 2333–2349. [Google Scholar] [CrossRef] [PubMed]
- Qin, L.; Zeng, H.; Zhao, D. Requirement of protein kinase D tyrosine phosphorylation for VEGF-A165-induced angiogenesis through its interaction and regulation of phospholipase Cgamma phosphorylation. J. Biol. Chem. 2006, 281, 32550–32558. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Niles, A.L.; Moravec, R.A.; Eric Hesselberth, P.; Scurria, M.A.; Daily, W.J.; Riss, T.L. A homogeneous assay to measure live and dead cells in the same sample by detecting different protease markers. Anal. Biochem. 2007, 366, 197–206. [Google Scholar] [CrossRef] [PubMed]
- Larson, E.M.; Doughman, D.J.; Gregerson, D.S.; Obritsch, W.F. A new, simple, nonradioactive, nontoxic in vitro assay to monitor corneal endothelial cell viability. Investig. Ophthalmol. Vis. Sci. 1997, 38, 1929–1933. [Google Scholar] [PubMed]
- Arnaoutova, I.; Kleinman, H.K. In vitro angiogenesis: Endothelial cell tube formation on gelled basement membrane extract. Nat. Protoc. 2010, 5, 628–635. [Google Scholar] [CrossRef] [PubMed]
- Greenway, F.L.; Liu, Z.; Yu, Y.; Caruso, M.K.; Roberts, A.T.; Lyons, J.; Schwimer, J.E.; Gupta, A.K.; Bellanger, D.E.; Guillot, T.S.; et al. An assay to measure angiogenesis in human fat tissue. Obes. Surg. 2007, 17, 510–515. [Google Scholar] [CrossRef] [PubMed]
- Seano, G.; Chiaverina, G.; Gagliardi, P.A.; di Blasio, L.; Sessa, R.; Bussolino, F.; Primo, L. Modeling human tumor angiogenesis in a three-dimensional culture system. Blood 2013, 121, e129–e137. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Baker, M.; Robinson, S.D.; Lechertier, T.; Barber, P.R.; Tavora, B.; D’Amico, G.; Jones, D.T.; Vojnovic, B.; Hodivala-Dilke, K. Use of the mouse aortic ring assay to study angiogenesis. Nat. Protoc. 2011, 7, 89–104. [Google Scholar] [CrossRef] [PubMed]
- Akhtar, N.; Dickerson, E.B.; Auerbach, R. The sponge/Matrigel angiogenesis assay. Angiogenesis 2002, 5, 75–80. [Google Scholar] [CrossRef] [PubMed]
- Limbourg, A.; Korff, T.; Napp, L.C.; Schaper, W.; Drexler, H.; Limbourg, F.P. Evaluation of postnatal arteriogenesis and angiogenesis in a mouse model of hind-limb ischemia. Nat. Protoc. 2009, 4, 1737–1746. [Google Scholar] [CrossRef] [PubMed]
- Ribatti, D.; Gualandris, A.; Bastaki, M.; Vacca, A.; Iurlaro, M.; Roncali, L.; Presta, M. New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: The gelatin sponge/chorioallantoic membrane assay. J. Vasc. Res. 1997, 34, 455–463. [Google Scholar] [CrossRef] [PubMed]
- Passaniti, A.; Taylor, R.M.; Pili, R.; Guo, Y.; Long, P.V.; Haney, J.A.; Pauly, R.R.; Grant, D.S.; Martin, G.R. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Investig. 1992, 67, 519–528. [Google Scholar] [PubMed]
- Isogai, S.; Horiguchi, M.; Weinstein, B.M. The vascular anatomy of the developing zebrafish: An atlas of embryonic and early larval development. Dev. Biol. 2001, 230, 278–301. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chimote, G.; Sreenivasan, J.; Pawar, N.; Subramanian, J.; Sivaramakrishnan, H.; Sharma, S. Comparison of effects of anti-angiogenic agents in the zebrafish efficacy-toxicity model for translational anti-angiogenic drug discovery. Drug. Des. Dev. Ther. 2014, 8, 1107–1123. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lyons, M.S.; Bell, B.; Stainier, D.; Peters, K.G. Isolation of the zebrafish homologues for the tie-1 and tie-2 endothelium-specific receptor tyrosine kinases. Dev. Dyn. 1998, 212, 133–140. [Google Scholar] [CrossRef] [PubMed]
- Liang, D.; Chang, J.R.; Chin, A.J.; Smith, A.; Kelly, C.; Weinberg, E.S.; Ge, R. The role of vascular endothelial growth factor (VEGF) in vasculogenesis, angiogenesis, and hematopoiesis in zebrafish development. Mech. Dev. 2001, 108, 29–43. [Google Scholar] [CrossRef] [PubMed]
- Lawson, N.D.; Scheer, N.; Pham, V.N.; Kim, C.H.; Chitnis, A.B.; Campos-Ortega, J.A.; Weinstein, B.M. Notch signaling is required for arterial-venous differentiation during embryonic vascular development. Development 2001, 128, 3675–3683. [Google Scholar] [PubMed]
- Gerhardt, H.; Golding, M.; Fruttiger, M.; Ruhrberg, C.; Lundkvist, A.; Abramsson, A.; Jeltsch, M.; Mitchell, C.; Alitalo, K.; Shima, D.; et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J. Cell Biol. 2003, 161, 1163–1177. [Google Scholar] [CrossRef] [PubMed]
- Kimura, E.; Deguchi, T.; Kamei, Y.; Shoji, W.; Yuba, S.; Hitomi, J. Application of infrared laser to the zebrafish vascular system: Gene induction, tracing, and ablation of single endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2013, 33, 1264–1270. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Herwig, L.; Blum, Y.; Krudewig, A.; Ellertsdottir, E.; Lenard, A.; Belting, H.G.; Affolter, M. Distinct cellular mechanisms of blood vessel fusion in the zebrafish embryo. Curr. Biol. 2011, 21, 1942–1948. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Raghunath, M.; Sy Wong, Y.; Farooq, M.; Ge, R. Pharmacologically induced angiogenesis in transgenic zebrafish. Biochem. Biophys. Res. Commun. 2009, 378, 766–771. [Google Scholar] [CrossRef] [PubMed]
- Taylor, K.L.; Grant, N.J.; Temperley, N.D.; Patton, E.E. Small molecule screening in zebrafish: An in vivo approach to identifying new chemical tools and drug leads. Cell Commun. Signal. 2010, 8, 11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cheng, H.; Kari, G.; Dicker, A.P.; Rodeck, U.; Koch, W.J.; Force, T. A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. Circ. Res. 2011, 109, 1401–1409. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cui, G.; Chen, H.; Cui, W.; Guo, X.; Fang, J.; Liu, A.; Chen, Y.; Lee, S.M. FGF2 Prevents Sunitinib-Induced Cardiotoxicity in Zebrafish and Cardiomyoblast H9c2 Cells. Cardiovasc. Toxicol. 2016, 16, 46–53. [Google Scholar] [CrossRef] [PubMed]
- Qu, Y.; Gharbi, N.; Yuan, X.; Olsen, J.R.; Blicher, P.; Dalhus, B.; Brokstad, K.A.; Lin, B.; Øyan, A.M.; Zhang, W.; et al. Axitinib blocks Wnt/β-catenin signaling and directs asymmetric cell division in cancer. Proc. Natl. Acad. Sci. USA 2016, 113, 9339–9344. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wu, J.Q.; Fan, R.Y.; Zhang, S.R.; Li, C.Y.; Shen, L.Z.; Wei, P.; He, Z.H.; He, M.F. A systematical comparison of anti-angiogenesis and anti-cancer efficacy of ramucirumab, apatinib, regorafenib and cabozantinib in zebrafish model. Life Sci. 2020, 247, 117402. [Google Scholar] [CrossRef] [PubMed]
- Langenau, D.M.; Traver, D.; Ferrando, A.A.; Kutok, J.L.; Aster, J.C.; Kanki, J.P.; Lin, S.; Prochownik, E.; Trede, N.S.; Zon, L.I.; et al. Myc-induced T cell leukemia in transgenic zebrafish. Science 2003, 299, 887–890. [Google Scholar] [CrossRef] [Green Version]
- Ablain, J.; Xu, M.; Rothschild, H.; Jordan, R.C.; Mito, J.K.; Daniels, B.H.; Bell, C.F.; Joseph, N.M.; Wu, H.; Bastian, B.C.; et al. Human tumor genomics and zebrafish modeling identify SPRED1 loss as a driver of mucosal melanoma. Science 2018, 362, 1055–1060. [Google Scholar] [CrossRef] [Green Version]
- Hwang, W.Y.; Fu, Y.; Reyon, D.; Maeder, M.L.; Tsai, S.Q.; Sander, J.D.; Peterson, R.T.; Yeh, J.R.; Joung, J.K. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat. Biotechnol. 2013, 31, 227–229. [Google Scholar] [CrossRef]
- Corkery, D.P.; Dellaire, G.; Berman, J.N. Leukaemia xenotransplantation in zebrafish-chemotherapy response assay in vivo. Br. J. Haematol. 2011, 153, 786–789. [Google Scholar] [CrossRef] [PubMed]
- Trede, N.S.; Langenau, D.M.; Traver, D.; Look, A.T.; Zon, L.I. The use of zebrafish to understand immunity. Immunity 2004, 20, 367–379. [Google Scholar] [CrossRef] [Green Version]
- Langenau, D.M.; Ferrando, A.A.; Traver, D.; Kutok, J.L.; Hezel, J.P.; Kanki, J.P.; Zon, L.I.; Look, A.T.; Trede, N.S. In vivo tracking of T cell development, ablation, and engraftment in transgenic zebrafish. Proc. Natl. Acad. Sci. USA 2004, 101, 7369–7374. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yan, C.; Brunson, D.C.; Tang, Q.; Do, D.; Iftimia, N.A.; Moore, J.C.; Hayes, M.N.; Welker, A.M.; Garcia, E.G.; Dubash, T.D.; et al. Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish. Cell 2019, 177, 1903–1914.e14. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.; Ma, Q.; Zhang, S.; Liu, H.; Zhao, B.; Du, B.; Wang, W.; Lin, P.; Zhang, Z.; Zhong, Y.; et al. Digoxin Enhances the Anticancer Effect on Non-Small Cell Lung Cancer While Reducing the Cardiotoxicity of Adriamycin. Front. Pharmacol. 2020, 11, 186. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tu, W.M.; Huang, X.C.; Chen, Y.L.; Luo, Y.L.; Liau, I.; Hsu, H.Y. Longitudinal and quantitative assessment platform for concurrent analysis of anti-tumor efficacy and cardiotoxicity of nano-formulated medication in vivo. Anal. Chim. Acta 2020, 1095, 129–137. [Google Scholar] [CrossRef] [PubMed]
- Fazio, M.; Ablain, J.; Chuan, Y.; Langenau, D.M.; Zon, L.I. Zebrafish patient avatars in cancer biology and precision cancer therapy. Nat. Rev. Cancer 2020, 20, 263–273. [Google Scholar] [CrossRef] [PubMed]
- Yao, Y.; Wang, L.; Wang, X. Modeling of Solid-Tumor Microenvironment in Zebrafish (Danio rerio) Larvae. Adv. Exp. Med. Biol. 2020, 1219, 413–428. [Google Scholar] [CrossRef] [PubMed]
- Dang, M.; Henderson, R.E.; Garraway, L.A.; Zon, L.I. Long-term drug administration in the adult zebrafish using oral gavage for cancer preclinical studies. Dis. Models Mech. 2016, 9, 811–820. [Google Scholar] [CrossRef] [Green Version]
- Burridge, P.W.; Li, Y.F.; Matsa, E.; Wu, H.; Ong, S.G.; Sharma, A.; Holmström, A.; Chang, A.C.; Coronado, M.J.; Ebert, A.D.; et al. Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. Nat. Med. 2016, 22, 547–556. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gintant, G.; Burridge, P.; Gepstein, L.; Harding, S.; Herron, T.; Hong, C.; Jalife, J.; Wu, J.C. Use of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical Cancer Drug Cardiotoxicity Testing: A Scientific Statement from the American Heart Association. Circ. Res. 2019, 125, e75–e92. [Google Scholar] [CrossRef] [PubMed]
- Lam, P.Y.; Kutchukian, P.; Anand, R.; Imbriglio, J.; Andrews, C.; Padilla, H.; Vohra, A.; Lane, S.; Parker, D.L.; Taracido, I.C. Cyp1 Inhibition Prevents Doxorubicin-Induced Cardiomyopathy in a Zebrafish Heart-Failure Model. Chembiochem 2020, 21, 1905–1910. [Google Scholar] [CrossRef] [PubMed]
- Ding, Y.; Sun, X.; Huang, W.; Hoage, T.; Redfield, M.; Kushwaha, S.; Sivasubbu, S.; Lin, X.; Ekker, S.; Xu, X. Haploinsufficiency of target of rapamycin attenuates cardiomyopathies in adult zebrafish. Circ. Res. 2011, 109, 658–669. [Google Scholar] [CrossRef] [PubMed]
- Han, Y.; Zhang, J.P.; Qian, J.Q.; Hu, C.Q. Cardiotoxicity evaluation of anthracyclines in zebrafish (Danio rerio). J. Appl. Toxicol. 2015, 35, 241–252. [Google Scholar] [CrossRef] [PubMed]
- Calienni, M.N.; Cagel, M.; Montanari, J.; Moretton, M.A.; Prieto, M.J.; Chiappetta, D.A.; Alonso, S.D.V. Zebrafish (Danio rerio) model as an early stage screening tool to study the biodistribution and toxicity profile of doxorubicin-loaded mixed micelles. Toxicol. Appl. Pharmacol. 2018, 357, 106–114. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhu, J.J.; Xu, Y.Q.; He, J.H.; Yu, H.P.; Huang, C.J.; Gao, J.M.; Dong, Q.X.; Xuan, Y.X.; Li, C.Q. Human cardiotoxic drugs delivered by soaking and microinjection induce cardiovascular toxicity in zebrafish. J. Appl. Toxicol. 2014, 34, 139–148. [Google Scholar] [CrossRef] [PubMed]
- Katayama, M.; Imai, Y.; Hashimoto, H.; Kurata, M.; Nagai, K.; Tamita, K.; Morioka, S.; Frukawa, Y. Fulminant fata cardiotoxicity following cyclophosphamide therapy. J. Cardiol. 2009, 54, 330–334. [Google Scholar] [CrossRef] [Green Version]
- Nakamura, S.; Aoki, M.; Mori, A.; Nakahara, T.; Sakamoto, K.; Ishii, K. Analysis of cardiac toxicity caused by cyclophosphamide in the H9c2 cell line and isolated and perfused rat hearts. Gan To Kagaku Ryoho 2010, 37, 677–680. [Google Scholar]
- Singh, A.P.; Glennon, M.S.; Umbarkar, P.; Gupte, M.; Galindo, C.L.; Zhang, Q.; Force, T.; Becker, J.R.; Lal, H. Ponatinib-induced cardiotoxicity: Delineating the signalling mechanisms and potential rescue strategies. Cardiovasc. Res. 2019, 115, 966–977. [Google Scholar] [CrossRef] [PubMed]
- Jin, Y.; Wei, L.; Jiang, Q.; Song, X.; Teng, C.; Fan, C.; Lv, Y.; Liu, Y.; Shen, W.; Li, L.; et al. Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model. Sci. Rep. 2018, 8, 15837. [Google Scholar] [CrossRef] [PubMed]
- Zakaria, Z.Z.; Benslimane, F.M.; Nasrallah, G.K.; Shurbaji, S.; Younes, N.N.; Mraiche, F.; Da’as, S.I.; Yalcin, H.C. Using Zebrafish for Investigating the Molecular Mechanisms of Drug-Induced Cardiotoxicity. Biomed. Res. Int. 2018, 2018, 1642684. [Google Scholar] [CrossRef] [PubMed]
- Chi, N.C.; Bussen, M.; Brand-Arzamendi, K.; Ding, C.; Olgin, J.E.; Shaw, R.M.; Martin, G.R.; Stainier, D.Y.R. Cardiac conduction is required to preserve cardiac chamber morphology. Proc. Natl. Acad. Sci. USA 2010, 107, 14662–14667. [Google Scholar] [CrossRef] [Green Version]
- González-Rosa, J.M.; Burns, C.E.; Burns, C.G. Zebrafish heart regeneration: 15 Years of discoveries. Regeneration 2017, 4, 105–123. [Google Scholar] [CrossRef] [PubMed]
- Jopling, C.; Sleep, E.; Raya, M.; Martí, M.; Raya, A.; Izpisúa Belmonte, J.C. Zebrafish heart regeneration occurs by cardiomyocyte dedifferentiation and proliferation. Nature 2010, 464, 606–609. [Google Scholar] [CrossRef] [PubMed]
- Wu, J.Q.; Zhai, J.; Li, C.Y.; Tan, A.M.; Wei, P.; Shen, L.Z.; He, M.F. Patient-derived xenograft in zebrafish embryos: A new platform for translational research in gastric cancer. J. Exp. Clin. Cancer Res. 2017, 36, 160. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cassar, S.; Adatto, I.; Freeman, J.L.; Gamse, J.T.; Iturria, I.; Lawrance, C.; Muriana, A.; Peterson, R.T.; Van Cruchten, S.; Zon, L.I. Use of Zebrafish in Drug Discovery Toxicology. Chem. Res. Toxicol. 2020, 33, 95–118. [Google Scholar] [CrossRef] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Lane, S.; More, L.A.; Asnani, A. Zebrafish Models of Cancer Therapy-Induced Cardiovascular Toxicity. J. Cardiovasc. Dev. Dis. 2021, 8, 8. https://doi.org/10.3390/jcdd8020008
Lane S, More LA, Asnani A. Zebrafish Models of Cancer Therapy-Induced Cardiovascular Toxicity. Journal of Cardiovascular Development and Disease. 2021; 8(2):8. https://doi.org/10.3390/jcdd8020008
Chicago/Turabian StyleLane, Sarah, Luis Alberto More, and Aarti Asnani. 2021. "Zebrafish Models of Cancer Therapy-Induced Cardiovascular Toxicity" Journal of Cardiovascular Development and Disease 8, no. 2: 8. https://doi.org/10.3390/jcdd8020008